Showing results (291-300 of 463) with videos related to

Sort By:
Pageof 47
Pharmacogenetics and Genomics|July 12, 2014
Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantationÖzlem Tapirdamaz, Dennis A Hesselink, Samira el Bouazzaoui, et al.
British Journal of Clinical Pharmacology|August 19, 2023
Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort studyMaaike R Schagen, Asiye Nur Ulu, Marith I Francke, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 30, 2015
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney TransplantationN Shuker, R Bouamar, R H N van Schaik, et al.
Frontiers in Pharmacology|May 17, 2021
Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric PracticeR van Westrhenen, R H N van Schaik, T van Gelder, et al.
Journal of the National Cancer Institute|November 4, 2004
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probesRon H J Mathijssen, Floris A de Jong, Ron H N van Schaik, et al.
Journal of Neurology|August 31, 2006
Comparison of CMT1A and CMT2: similarities and differencesHenriette M E Bienfait, Camiel Verhamme, Ivo N van Schaik, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 8, 2023
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scaleBram C Agema, Sanne M Buijs, Sebastiaan D T Sassen, et al.
Pharmacogenetics|May 7, 2004
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumonLoes E Visser, Martin van Vliet, Ron H N van Schaik, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2020
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancerBodine P S Belderbos, Mirjam de With, Rajbir K Singh, et al.
The Lancet. Neurology|November 11, 2017
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialIvo N van Schaik, Vera Bril, Nan van Geloven, et al.
Pageof 47